What is Alkermes's LUMRYZ — revenue?

Alkermes (ALKS) reported LUMRYZ — revenue of $96.57M in Q2 2026.

What does LUMRYZ — revenue mean?

This metric represents the net revenue recognized from the sale of the pharmaceutical product LUMRYZ, excluding any taxes collected from customers. It reflects the commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. This figure is critical for assessing the product's lifecycle stage, market penetration, and contribution to the company's overall top-line growth.

Alkermes (ALKS) LUMRYZ — Revenue

Screener

Other product segments

Vivitrol

$124.45M—

Aristada And Aristada Initio

$96.72M—

LYBALVI

$93.98M—

Similar metrics at other companies

HRO

HROWOther Revenues — Revenue

$73K-15.1%

ORCLCloud Revenues — Revenue

$9.91B+47.1%

ORCLSoftware Revenues — Revenue

$6.82B-2.1%

OWLPerformance revenues — Revenue

$6.07M-3.9%

EAT

EATFranchise revenues — Revenue

$14.7M+21.5%

CNKOther Revenues — Revenue

$113.1M+18.2%

Other financials

Income statement

See full

Revenue$496.0M+27.0%

Gross profit$397.9M+16.6%

Operating income$18.4M-80.3%

Net income$501.0K-99.4%

EPS (diluted)$0.00-100%

Balance sheet

See full

Cash & equivalents$511.5M-1.9%

Total debt$1.6B+2,064%

Total equity$1.8B+11.3%

Total assets$4.4B+95.0%

Cash flow

See full

Operating cash flow-$165.7M-268%

CapEx$8.1M-37.4%

Free cash flow-$169.8M-291%

Valuation

See full

Market cap$8.32B+89.9%

Enterprise value$9.38B+139%

P/E125.9×+113×

P/S5×+2.1×

Profitability

See full

Gross margin84.6%-0.6pp

Operating margin7%-17.8pp

Net margin4%-19.2pp

FCF margin14.2%-17.6pp

Returns & leverage

See full

Return on equity3.9%-20.1pp

Debt / equity0.9×+0.8×

Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed: Jul 28, 2026, 9:22 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-319022

(In thousands)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
VIVITROL	$124,454	$121,660	$236,888	$222,656
ARISTADA and ARISTADA INITIO	96,719	101,295	190,543	174,770
LYBALVI	93,979	84,280	186,343	154,302
LUMRYZ	96,572	—	136,064	—
Total product sales, net	$411,724	$307,235	$749,838	$551,728

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's LUMRYZ — revenue?: Alkermes (ALKS) reported LUMRYZ — revenue of $96.57M in Q2 2026.
What does LUMRYZ — revenue mean?: This metric represents the net revenue recognized from the sale of the pharmaceutical product LUMRYZ, excluding any taxes collected from customers. It reflects the commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. This figure is critical for assessing the product's lifecycle stage, market penetration, and contribution to the company's overall top-line growth.